Beta-blockers in the treatment of hypertension

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001372" target="_blank" >RIV/00064190:_____/25:10001372 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.33678/cor.2025.047" target="_blank" >https://doi.org/10.33678/cor.2025.047</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.33678/cor.2025.047" target="_blank" >10.33678/cor.2025.047</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Beta-blockers in the treatment of hypertension

Popis výsledku v původním jazyce

Beta-blockers are currently among the five major classes of antihypertensive drugs with a proven reduction in cardiovascular (CV) morbidity and mortality. The latest recommendations of the European Society of Hypertension (ESH) have reassessed their position in the treatment of hypertension and have included them among the drugs of the first choice in the treatment of hypertension. Prevention of cardiovascular (CV) complications in hypertension has been documented by large clinical trials for atenolol, metoprolol, oxprenolol, and propranolol. Beta-blockers are widely used in the management of hypertension accompanied by comorbidities such as chronic coronary syndrome, post-myocardial infarction, arrhythmias, angina pectoris, heart failure with reduced or preserved ejection fraction, acute coronary syndrome, atrial fibrillation, as well as in women of reproductive age or planning pregnancy and in the treatment of hypertension in pregnancy. Administration of beta-blockers is particularly indicated in hypertensive patients with a resting heart rate &gt; 80/min. The beneficial effects of beta-blockers have been demonstrated in more than fifty clinical conditions, some of which are outside the field of CV disease. Beta-blockers may also be used in pregnancy: labetalol is considered a drug of choice for treatment of hypertension in pregnancy, while metoprolol is safe in a later phase of pregnancy being also compatible with breastfeeding.

Název v anglickém jazyce

Beta-blockers in the treatment of hypertension

Popis výsledku anglicky

Beta-blockers are currently among the five major classes of antihypertensive drugs with a proven reduction in cardiovascular (CV) morbidity and mortality. The latest recommendations of the European Society of Hypertension (ESH) have reassessed their position in the treatment of hypertension and have included them among the drugs of the first choice in the treatment of hypertension. Prevention of cardiovascular (CV) complications in hypertension has been documented by large clinical trials for atenolol, metoprolol, oxprenolol, and propranolol. Beta-blockers are widely used in the management of hypertension accompanied by comorbidities such as chronic coronary syndrome, post-myocardial infarction, arrhythmias, angina pectoris, heart failure with reduced or preserved ejection fraction, acute coronary syndrome, atrial fibrillation, as well as in women of reproductive age or planning pregnancy and in the treatment of hypertension in pregnancy. Administration of beta-blockers is particularly indicated in hypertensive patients with a resting heart rate &gt; 80/min. The beneficial effects of beta-blockers have been demonstrated in more than fifty clinical conditions, some of which are outside the field of CV disease. Beta-blockers may also be used in pregnancy: labetalol is considered a drug of choice for treatment of hypertension in pregnancy, while metoprolol is safe in a later phase of pregnancy being also compatible with breastfeeding.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

COR ET VASA

ISSN

0010-8650

e-ISSN

1803-7712

Svazek periodika

67

Číslo periodika v rámci svazku

Supplement 2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

18-25

Kód UT WoS článku

001537852900004

EID výsledku v databázi Scopus

2-s2.0-105005842966